All In Biotech

NDA 021146 · Hospira

Atropine Sulfate

Atropine Sulfate · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jul 9, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

414

74 Phase 3, 30 recruiting

FAERS reports

2,540

2,136 serious, 398 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

Atropine Sulfate Injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life-threatening muscarinic effects. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 9, 2001 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
3 products under this application
  • ATROPINE SULFATE · ATROPINE SULFATE 1MG/10ML (0.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • ATROPINE SULFATE · ATROPINE SULFATE 0.5MG/5ML (0.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • ATROPINE SULFATE · ATROPINE SULFATE 0.25MG/5ML (0.05MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.

All 414 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective315
  • off label use211
  • macular degeneration199
  • nausea193
  • pyrexia161
  • diarrhoea149
  • pain136
  • malaise132
  • headache129
  • weight decreased120
  • death118
  • constipation115

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200455
200562
200650
200755
200872
200945
201075
201167
201271
201360
201467
201574
2016112
201790
2018122
2019181
2020158
2021146
2022226
2023231
2024232
2025185
2026103

Recalls

1 FDA enforcement reports for this application.

  • Dec 21, 2023 · Class I · Ongoing

    Presence of Particulate Matter; identified as glass

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05).

  • Current · updated Nov 9, 2026

    Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Atropine Sulfate (Atropine Sulfate/PF)

2024 spending

$26K

Beneficiaries

389

541 claims

Per beneficiary

$66

$4.08 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$16,880
2024$25,522

Part D: Atropine Sulfate* (Atropine Sulfate)

2024 spending

$8.9M

Beneficiaries

122,395

214,955 claims

Per beneficiary

$73

$7.76 per unit

View as table
YearSpending
2020$1,723
2021$92,485
2022$5,163,655
2023$8,217,428
2024$8,948,517

Part B: Atropine Sulfate* (Atropine Sulfate*) · HCPCS J0461

2024 spending

$184K

Beneficiaries

9,157

50,874 claims

Per beneficiary

$20

2024 ASP limit $0.09 per unit

View as table
YearSpending
2020$168,296
2021$197,768
2022$182,791
2023$189,665
2024$184,194

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,885 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.